ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2300

Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?

John Zawidniak1 and John Waterman2, 1Rheumatology, University of Connecticut, Farmington, CT, 2Rheumatology, Connecticut VA Healthcare System, Newington, CT

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Bone density, glucocorticoids, Guidelines and osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a well-established and well-studied phenomenon that is a sequela of the treatment of many inflammatory diseases. Many studies over the years have looked at compliance with guidelines for the prevention and treatment of GIOP. Previous studies have shown compliance with recommendations to be quite poor in regards to DXA screening, as well as calcium and vitamin D supplementation. This study aimed to give a current look at this issue, particularly in light of the most recent release of ACR GIOP guidelines in 2017, to see if compliance has improved over the years.

Methods: Patients who had received a prescription of prednisone between July 2016 to July 2017 from the VA Connecticut Health System were identified. The first 300 patient’s charts were reviewed. Patients were excluded if they had received one time tapers of prednisone or if they were receiving prednisone for malignancy and were since deceased. Subsequently 266 patients were included for analysis (on prednisone for ≥3 months, dose ≥2.5mg daily, and any indication). Data on age, last dosage of prednisone, duration of treatment, diagnosis, DXA status, DXA results, vitamin D levels, and whether patients were on calcium or vitamin D supplementation were collected.

Results: Of 266 patients included for analysis, mean age was 71 (standard deviation 12 years), mean dosage 7.65mg (range 1-50mg). 120 patients had undergone DXA examination (45.1%), 146 had not. The most frequent diagnoses’ were RA with 49 patients, COPD 40, PMR 37, transplant 23, and myasthenia gravis 13. Prescriber specialty 114 patients rheumatology, 50 primary care physician, 24 pulmonary, 19 nephrology, 15 each hematology-oncology and neurology, 29 other. Rheumatologists had a rate of DXA scans of 53.5%, primary care physicians 38%, pulmonary 29.2%, renal 42.1%, hematology-oncology 33.3%, and neurology 46.67%. Taking into consideration the 2017 guidelines, with patients ≥40 years of age, 45.9% of appropriate patients underwent DXA, 54% did not. Per 2017 guidelines 51.7% were appropriately on calcium supplementation and 57.5% appropriately on vitamin D supplementation.

Conclusion: There have been many studies over the years regarding compliance with guidelines for GIOP. In this particular study, as seen previously, we show poor compliance with only 45.1% of patients appropriately undergoing DXA screening. If accounting for the 2017 guidelines in the cohort of patients ≥40 years of age this improves to 45.9%. Patients are still largely not undergoing proper screening and even when they do a large proportion, 48.3% for calcium, 42.4% for vitamin D are not receiving the appropriate calcium and vitamin D supplementation. With each new iteration of guidelines for GIOP it becomes imperative to adjust practice habits appropriately. Unfortunately study after study shows this is not occurring. Given the continued poor compliance on the part of providers it is worth considering a reduction in frequency of revision of guidelines and better provider education to finally lead to improved compliance.


Disclosure: J. Zawidniak, None; J. Waterman, None.

To cite this abstract in AMA style:

Zawidniak J, Waterman J. Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/compliance-with-screening-and-supplementation-guidelines-for-glucocorticoid-induced-osteoporosis-how-bad-did-we-do-this-time/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/compliance-with-screening-and-supplementation-guidelines-for-glucocorticoid-induced-osteoporosis-how-bad-did-we-do-this-time/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology